Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Malachite Innovations, Inc. VBIO OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
35/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Malachite Innovations, Inc. (VBIO) is a Biotechnology company in the Healthcare sector, currently trading at $0.39. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $880,851 (loss), growing at -69.7%/yr. Net profit margin is 0% (thin). Gross margin is 23.9% (+0 pp trend).

Balance sheet: total debt is $0 against $863,394 equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 26.54 (strong liquidity). Debt-to-assets is 0%. Total assets: $896,834.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 25/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

VBIO SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 25/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VBIO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
VBIO: -100%/yr revenue is, -69.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet VBIO: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 26.54 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
25/100
VBIO: Gross margin is 23.9% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 25/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.36015-0.4195
Volume64.22K
Avg Volume (30D)98.13K
Beta (1Y)4.11
Share Statistics
EPS (TTM)-0.02
Shares Outstanding$50.84M
IPO Date2022-01-31
Employees3
CEOMichael R. Cavanaugh CPA,
Financial Highlights & Ratios
EBITDA$-880.85K
Net Income$-880.85K
Operating Income$-2.34M
Total Cash$884.14K
Net Debt$-884.14K
Total Assets$896.83K
Price / Earnings (P/E)-22.5
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD

Price Chart

Track all markets on TradingView
VBIO
Malachite Innovations, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.36 52WK RANGE 0.42

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message